Claims for Patent: 5,350,741

Summary for Patent: 5,350,741

Title:	Enteric formulations of physiologically active peptides and proteins
Abstract:	An enteric formulation for a proteinous drug which protects it from enzymatic degradation and promotes its uptake by the intestinal tract when administered orally, comprises either a solid mass of an intimate mixture of the drug, a nontoxic nonionic surfactant, and an enteric material, or a solid mass of an intimate mixture of the drug with the nonionic surfactant covered by a discrete enteric coating.
Inventor(s):	Takada; Kanji (Shimogyo-ku, Kyoto-shi, Kyoto 600, JP)
Assignee:
Application Number:	07/888,324
Patent Claims:	1. A solid enteric pharmaceutical formulation consisting of a particulate intimate physical mixture of a (a) physiologically active peptide or protein, (b) a nontoxic nonionic surfactant, (c) a pharmaceutically acceptable solid organic acid selected from the group consisting of tartaric, malonic, maleic, malic, citric and cinnamic acids (d), at least 50 wt. %, based on the weight of the pharmaceutical formulation, of a pharmaceutically acceptable, enteric polymer which is soluble in a volatile organic solvent and which dissolves selectively from the mixture in duodenal juice when the mixture is ingested and, optionally, (e) either or both of a pharmaceutically acceptable solid diluent and an effervescing agent. 2. The pharmaceutical formulation of claim 1 wherein the effervescing agent is sodium bicarbonate. 3. The pharmaceutical formulation of claim 1 which contains not less than 80 wt. %, based on the weight of the formulation, of the enteric polymer. 4. The pharmaceutical formulation of claim 1, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A. 5. The pharmaceutical formulation of claim 1, wherein the organic acid is L-tartaric acid. 6. The pharmaceutical formulation of claim 1, wherein the formulation is in granule form. 7. The pharmaceutical formulation of claim 1, in tablet, capsule or other solid unit dosage form. 8. The pharmaceutical formulation according to claim 1, wherein the surfactant is selected from the group consisting of sorbitan fatty acid ester, polyoxyethylene-sorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer. 9. The enteric pharmaceutical formulation according to claim 1, in the form of a particulate mixture of the physiologically active peptide or protein and the surfactant, with an enteric coating on the particles of the mixture of the enteric material. 10. The enteric pharmaceutical formulation according to claim 9, wherein the surfactant is selected from the group consisting of sorbitan fatty acid ester, polyoxyethylenesorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxy propylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer. 11. An enteric pharmaceutical formulation according to claim 10, wherein the physiologically active peptide or protein is selected from the group consisting of angiotensin II antagonist peptide, bradykinin, calcitonin-gene associated factor, tissue plasminogen activators, cholecystokinin, delta sleep-inducing peptide (DSIP), .beta.-endorphin, atriopeptin, .alpha.-and .beta.-melanocyte-stimulating hormone, nerve peptide, nerve growth factor (NGF), gastrin antagonist peptide, neurotensin, somatostatin, the colony-stimulating factors G-CSF and GM-CSF, interferon, thymopoietin, tumor necrosis factor, growth hormone, growth hormone-carrier protein complex, human atrial natriuretic peptide (HANP), insulin, luteinizing hormone-releasing factor (LHRH), streptokinase, erythropoietin, urokinase, lysozyme, vasopressin (8- lysine and 8-arginine), oxytocin, desmopressin, cytochrome C, histamine-releasing factor, platelet related growth factor, human chorionic gonadotropin (HCG), human growth hormone (HGH), adrenocorticotropin (ACTH), calcitonin, parathyroid hormone, Factor XIII, Factor IX, MSH release inhibiting factor, enkephalin, thyrotropin releasing hormone, interleukins and renin inhibitor peptides. 12. The pharmaceutical formulation according to claim 11, wherein the surfactant is selected from the group consisting of: sorbitan fatty acid ester, polyoxyethylene-sorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer. 13. The pharmaceutical formulation of claim 11, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A. 14. A solid ingestible enteric pharmaceutical formulation consisting of a solid particulate mixture of (a) a physiologically active peptide or protein, (b) a nontoxic nonionic surfactant, (c) a pharmaceutically acceptable solid organic acid selected from the group consisting of tartaric, malonic, maleic, malic, citric and cinnamic acids and, optionally, (d) an inert solid diluent; the particles of which are covered with at least 50 wt. %, based on the weight of the formulation, of a polymer as a discrete enteric coating which covers the surface of the individual particles of the mixture, which coating is soluble in a volatile organic solvent and dissolves selectively in duodenal juice when the mixture is ingested. 15. The pharmaceutical formulation of claim 14, wherein the effervescing agent is sodium bicarbonate. 16. The pharmaceutical formulation of claim 14, which contains not less than 80 wt. %, based on the weight of the formulation, of the enteric polymer. 17. The pharmaceutical formulation of claim 14, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A. 18. The pharmaceutical formulation of claim 14, wherein the organic acid is L-tartaric acid. 19. The pharmaceutical formulation of claim 14, wherein the formulation is in granule form. 20. The pharmaceutical formulation of claim 14, in tablet, capsule or other solid unit dosage form.

Details for Patent 5,350,741

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2011-09-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2011-09-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2011-09-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2011-09-27
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2011-09-27
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2011-09-27
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2011-09-27